A recent study found that patient assessments of symptoms are fit for purpose and can be used by adolescents with alopecia areata in clinical trials and practice.
A cross-sectional, noninterventional, qualitative study published in the British Journal of Dermatology found that the Scalp Hair Assessment PRO, PRO Measure for Eyebrows, PRO Measure for Eyelashes, PRO Measure for Nail Appearance, and PRO Measure for Eye Irritation were effective measures of self-reported symptoms among adolescents aged 12 to 17 years with alopecia areata (AA).
The researchers interviewed 11 adolescents for this study. All had greater than or equal to 50% scalp hair loss presently or in the past, and the adolescents had a mean (SD) age of 15.0 (1.5) years, had been diagnosed with AA for a mean of 5.9 (4.0) years, and had a mean of 69.6% (38.3%) scalp hair loss. At the time of the interview, 45% of participants were receiving treatment for AA.
Adolescents reported that scalp hair loss was the most bothersome symptom of AA for them, with more female than male participants (6 vs 1, respectively) rating scalp hair loss as most bothersome.
Participants described their current or previous amount of scalp hair qualitatively or as a percentage or fraction. There were 6 participants who did not think of the amount of hair that they had as a percentage, preferring qualitative means of explanation. All participants demonstrated an understanding of percentages, although 2 incorrectly guessed the percentage of hair that they had compared with their doctor’s assessment.
Participants reported that a median 80% of scalp hair coverage would be clinically meaningful and an indicator of treatment success after 9 to 12 months. All adolescents could provide responses to the Scalp Hair Assessment and understood the instructions for assessment.
All 11 participants were able to provide percentages of missing hair for each severity category, with 7 who found the task easy and 3 who expressed some confusion before understanding after a brief explanation. Most of the participants (7 of 10) preferred the measure with percentages whereas the remaining 3 preferred using descriptors. All participants thought they accurately rated their hair loss but deferred to doctor assessments.
All 11 adolescents understood and provided responses to the PRO Measure for Eyebrows, PRO Measure for Eyelashes, and PRO Measure for Nail Appearance with only minor problems reported. The photoguide for the assessment of nail appearance was helpful in providing an explanation for different nail damage descriptors.
Participants were confident in their ratings but felt a doctor’s rating would also be needed in a clinical trial, as the doctor would be most informed. The PRO Measure of Eye Irritation was similarly easy to understand for the participants.
There were some limitations to this study. The study was conducted only in the United States and may not be generalizable. The small sample size did not permit analysis of the data or the ability to draw conclusions based on age or sex. The adolescents may have been exposed to PRO tests prior. Some participants’ hair loss was assessed just prior to their interview, which may have influenced perceived hair loss.
The researchers concluded that the Scalp Hair Assessment PRO, PRO Measure for Eyebrows, PRO Measure for Eyelashes, PRO Measure for Nail Appearance and PRO Measure for Eye Irritation were assessments that could be used by adolescents with AA in clinical trials and clinical practice, subject to further psychometric evaluation.
Reference
Macey J, Kitchen H, Aldhouse NVJ, et al. A qualitative interview study to explore adolescents’ experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures. Br J Dermatol. 2022;186:849-860. doi:10.1111/bjd.20904
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
AI Dermatology Mobile Apps Have Critical Efficacy, Safety Gaps, Review Says
March 17th 2024This scoping review discovered potential risks and critical gaps in the efficacy, safety, and transparency of current artificial intelligence (AI) dermatology mobile apps, emphasizing the need for regulatory intervention.
Read More
Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa
March 11th 2024Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Read More